CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Novo Nordisk to present low-dose CagriSema trial results at ObesityWeek 2026

By Public Technologies
  • Novo Nordisk will present obesity research across 26 abstracts at ObesityWeek 2026, November 14-17 in Washington, D.C.
  • CagriSema presentations will examine weight loss at lower doses in REDEFINE 9 and weight-related quality of life in REDEFINE 1.
  • Wegovy studies will assess real-world weight outcomes, food noise and patient experience with oral and injectable treatments.
  • Full STEP Young results will cover investigational semaglutide injections for obesity in children ages 6 to under 12, with simultaneous publication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk